Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling
The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf wt ) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role f...
Gespeichert in:
Veröffentlicht in: | The EMBO journal 2012-05, Vol.31 (11), p.2629-2647 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2647 |
---|---|
container_issue | 11 |
container_start_page | 2629 |
container_title | The EMBO journal |
container_volume | 31 |
creator | Röring, Michael Herr, Ricarda Fiala, Gina J Heilmann, Katharina Braun, Sandra Eisenhardt, Anja E Halbach, Sebastian Capper, David von Deimling, Andreas Schamel, Wolfgang W Saunders, Darren N Brummer, Tilman |
description | The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf
wt
) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf
wt
and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf
V600E
, B‐Raf
insT
and B‐Raf
G469A
oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf
wt
, B‐Raf
V600E
displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf
wt
and Raf‐1
wt
mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation.
An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling. |
doi_str_mv | 10.1038/emboj.2012.100 |
format | Article |
fullrecord | <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3365413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1018369830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</originalsourceid><addsrcrecordid>eNptkUFv1DAQhS0EokvhyhFF4sKhaWfsteNckOh2KVQtIATt0XISJ3ibOFs7ge6_r5eUVUGcPE_zvfHYj5CXCIcITB6ZruhXhxSQRg2PyAznAlIKGX9MZkAFpnOU-R55FsIKALjM8CnZo5QjSDmfkebEhsG6cki8uRmtN51xQ1L3PtEusW7QsVPZzvitML7WpYlV8su2VTps1uYguRQAy0hXybV1Opi0MrpKjtOvuk6CbZxuW-ua5-RJrdtgXtyf--T7--W3xYf0_PPpx8W787TkwCEtBfICqZaCM50hzanJUJd5zQRWwHIoa5oVUvIKa1pwEIxjzWKh87wqIWf75O00dz0WnanK-BqvW7X2ttN-o3pt1d8dZ3-opv-pGBN8jiwOeHM_wPc3owmD6mwoTdtqZ_oxKASUTOSSQURf_4Ou-tHHB0-UyDnlIlKvHm60W-VPBhHIJiB-qtns-ghqm7D6nbDaJhw1qOXF8dlWxDo6jyZniCbXGP9wgf-5oyOdHDF1c7u7S_trJTKWcXX16VQtFldfzoBeqEt2B0ert4g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018695256</pqid></control><display><type>article</type><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><source>Springer Nature OA Free Journals</source><creator>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</creator><creatorcontrib>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</creatorcontrib><description>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf
wt
) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf
wt
and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf
V600E
, B‐Raf
insT
and B‐Raf
G469A
oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf
wt
, B‐Raf
V600E
displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf
wt
and Raf‐1
wt
mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation.
An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</description><identifier>ISSN: 0261-4189</identifier><identifier>EISSN: 1460-2075</identifier><identifier>DOI: 10.1038/emboj.2012.100</identifier><identifier>PMID: 22510884</identifier><identifier>CODEN: EMJODG</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>A-Raf ; Benzenesulfonates - pharmacology ; BRAF ; Caco-2 Cells ; Cancer ; EMBO24 ; EMBO37 ; Gene expression ; HCT116 Cells ; HT29 Cells ; Humans ; Indoles - pharmacology ; Kinases ; MAP Kinase Signaling System - drug effects ; MAP Kinase Signaling System - physiology ; Molecular biology ; Mutation ; Niacinamide - analogs & derivatives ; Phenylurea Compounds ; PLX 4032/4720 ; Protein Kinase Inhibitors - pharmacology ; Protein Multimerization - drug effects ; Protein Multimerization - physiology ; Proto-Oncogene Proteins B-raf - metabolism ; Pyridines - pharmacology ; Signal transduction ; sorafenib ; Sulfonamides - pharmacology ; V600E-specific antibody</subject><ispartof>The EMBO journal, 2012-05, Vol.31 (11), p.2629-2647</ispartof><rights>European Molecular Biology Organization 2012</rights><rights>Copyright © 2012 European Molecular Biology Organization</rights><rights>Copyright Nature Publishing Group May 30, 2012</rights><rights>Copyright © 2012, European Molecular Biology Organization 2012 European Molecular Biology Organization</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365413/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365413/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27903,27904,41099,42168,45553,45554,46387,46811,51554,53769,53771</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.1038/emboj.2012.100$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22510884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Röring, Michael</creatorcontrib><creatorcontrib>Herr, Ricarda</creatorcontrib><creatorcontrib>Fiala, Gina J</creatorcontrib><creatorcontrib>Heilmann, Katharina</creatorcontrib><creatorcontrib>Braun, Sandra</creatorcontrib><creatorcontrib>Eisenhardt, Anja E</creatorcontrib><creatorcontrib>Halbach, Sebastian</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Schamel, Wolfgang W</creatorcontrib><creatorcontrib>Saunders, Darren N</creatorcontrib><creatorcontrib>Brummer, Tilman</creatorcontrib><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><title>The EMBO journal</title><addtitle>EMBO J</addtitle><addtitle>EMBO J</addtitle><description>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf
wt
) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf
wt
and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf
V600E
, B‐Raf
insT
and B‐Raf
G469A
oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf
wt
, B‐Raf
V600E
displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf
wt
and Raf‐1
wt
mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation.
An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</description><subject>A-Raf</subject><subject>Benzenesulfonates - pharmacology</subject><subject>BRAF</subject><subject>Caco-2 Cells</subject><subject>Cancer</subject><subject>EMBO24</subject><subject>EMBO37</subject><subject>Gene expression</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Kinases</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>MAP Kinase Signaling System - physiology</subject><subject>Molecular biology</subject><subject>Mutation</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Phenylurea Compounds</subject><subject>PLX 4032/4720</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Multimerization - drug effects</subject><subject>Protein Multimerization - physiology</subject><subject>Proto-Oncogene Proteins B-raf - metabolism</subject><subject>Pyridines - pharmacology</subject><subject>Signal transduction</subject><subject>sorafenib</subject><subject>Sulfonamides - pharmacology</subject><subject>V600E-specific antibody</subject><issn>0261-4189</issn><issn>1460-2075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkUFv1DAQhS0EokvhyhFF4sKhaWfsteNckOh2KVQtIATt0XISJ3ibOFs7ge6_r5eUVUGcPE_zvfHYj5CXCIcITB6ZruhXhxSQRg2PyAznAlIKGX9MZkAFpnOU-R55FsIKALjM8CnZo5QjSDmfkebEhsG6cki8uRmtN51xQ1L3PtEusW7QsVPZzvitML7WpYlV8su2VTps1uYguRQAy0hXybV1Opi0MrpKjtOvuk6CbZxuW-ua5-RJrdtgXtyf--T7--W3xYf0_PPpx8W787TkwCEtBfICqZaCM50hzanJUJd5zQRWwHIoa5oVUvIKa1pwEIxjzWKh87wqIWf75O00dz0WnanK-BqvW7X2ttN-o3pt1d8dZ3-opv-pGBN8jiwOeHM_wPc3owmD6mwoTdtqZ_oxKASUTOSSQURf_4Ou-tHHB0-UyDnlIlKvHm60W-VPBhHIJiB-qtns-ghqm7D6nbDaJhw1qOXF8dlWxDo6jyZniCbXGP9wgf-5oyOdHDF1c7u7S_trJTKWcXX16VQtFldfzoBeqEt2B0ert4g</recordid><startdate>20120530</startdate><enddate>20120530</enddate><creator>Röring, Michael</creator><creator>Herr, Ricarda</creator><creator>Fiala, Gina J</creator><creator>Heilmann, Katharina</creator><creator>Braun, Sandra</creator><creator>Eisenhardt, Anja E</creator><creator>Halbach, Sebastian</creator><creator>Capper, David</creator><creator>von Deimling, Andreas</creator><creator>Schamel, Wolfgang W</creator><creator>Saunders, Darren N</creator><creator>Brummer, Tilman</creator><general>John Wiley & Sons, Ltd</general><general>Nature Publishing Group UK</general><general>Blackwell Publishing Ltd</general><general>Nature Publishing Group</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PCBAR</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120530</creationdate><title>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</title><author>Röring, Michael ; Herr, Ricarda ; Fiala, Gina J ; Heilmann, Katharina ; Braun, Sandra ; Eisenhardt, Anja E ; Halbach, Sebastian ; Capper, David ; von Deimling, Andreas ; Schamel, Wolfgang W ; Saunders, Darren N ; Brummer, Tilman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5050-c615b12a8653a71292e71ac9f361d0390cf27b885d1f2b506351f3b50a99dc093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>A-Raf</topic><topic>Benzenesulfonates - pharmacology</topic><topic>BRAF</topic><topic>Caco-2 Cells</topic><topic>Cancer</topic><topic>EMBO24</topic><topic>EMBO37</topic><topic>Gene expression</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Kinases</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>MAP Kinase Signaling System - physiology</topic><topic>Molecular biology</topic><topic>Mutation</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Phenylurea Compounds</topic><topic>PLX 4032/4720</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Multimerization - drug effects</topic><topic>Protein Multimerization - physiology</topic><topic>Proto-Oncogene Proteins B-raf - metabolism</topic><topic>Pyridines - pharmacology</topic><topic>Signal transduction</topic><topic>sorafenib</topic><topic>Sulfonamides - pharmacology</topic><topic>V600E-specific antibody</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Röring, Michael</creatorcontrib><creatorcontrib>Herr, Ricarda</creatorcontrib><creatorcontrib>Fiala, Gina J</creatorcontrib><creatorcontrib>Heilmann, Katharina</creatorcontrib><creatorcontrib>Braun, Sandra</creatorcontrib><creatorcontrib>Eisenhardt, Anja E</creatorcontrib><creatorcontrib>Halbach, Sebastian</creatorcontrib><creatorcontrib>Capper, David</creatorcontrib><creatorcontrib>von Deimling, Andreas</creatorcontrib><creatorcontrib>Schamel, Wolfgang W</creatorcontrib><creatorcontrib>Saunders, Darren N</creatorcontrib><creatorcontrib>Brummer, Tilman</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Earth, Atmospheric & Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Earth, Atmospheric & Aquatic Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The EMBO journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Röring, Michael</au><au>Herr, Ricarda</au><au>Fiala, Gina J</au><au>Heilmann, Katharina</au><au>Braun, Sandra</au><au>Eisenhardt, Anja E</au><au>Halbach, Sebastian</au><au>Capper, David</au><au>von Deimling, Andreas</au><au>Schamel, Wolfgang W</au><au>Saunders, Darren N</au><au>Brummer, Tilman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling</atitle><jtitle>The EMBO journal</jtitle><stitle>EMBO J</stitle><addtitle>EMBO J</addtitle><date>2012-05-30</date><risdate>2012</risdate><volume>31</volume><issue>11</issue><spage>2629</spage><epage>2647</epage><pages>2629-2647</pages><issn>0261-4189</issn><eissn>1460-2075</eissn><coden>EMJODG</coden><abstract>The dimerisation of Raf kinases involves a central cluster within the kinase domain, the dimer interface (DIF). Yet, the importance of the DIF for the signalling potential of wild‐type B‐Raf (B‐Raf
wt
) and its oncogenic counterparts remains unknown. Here, we show that the DIF plays a pivotal role for the activity of B‐Raf
wt
and several of its gain‐of‐function (g‐o‐f) mutants. In contrast, the B‐Raf
V600E
, B‐Raf
insT
and B‐Raf
G469A
oncoproteins are remarkably resistant to mutations in the DIF. However, compared with B‐Raf
wt
, B‐Raf
V600E
displays extended protomer contacts, increased homodimerisation and incorporation into larger protein complexes. In contrast, B‐Raf
wt
and Raf‐1
wt
mediated signalling triggered by oncogenic Ras as well as the paradoxical activation of Raf‐1 by kinase‐inactivated B‐Raf require an intact DIF. Surprisingly, the B‐Raf DIF is not required for dimerisation between Raf‐1 and B‐Raf, which was inactivated by the D594A mutation, sorafenib or PLX4720. This suggests that paradoxical MEK/ERK activation represents a two‐step mechanism consisting of dimerisation and DIF‐dependent transactivation. Our data further implicate the Raf DIF as a potential target against Ras‐driven Raf‐mediated (paradoxical) ERK activation.
An intact dimer interface (DIF) is required for both signalling and dimerisation in wild‐type Raf, but surprisingly for neither in certain oncogenic Raf versions. Paradoxical Raf activation reveals an additional layer of complexity, with the DIF now dispensable for dimerisation but required for signalling.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>22510884</pmid><doi>10.1038/emboj.2012.100</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | ISSN: 0261-4189 |
ispartof | The EMBO journal, 2012-05, Vol.31 (11), p.2629-2647 |
issn | 0261-4189 1460-2075 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3365413 |
source | Springer Nature OA Free Journals |
subjects | A-Raf Benzenesulfonates - pharmacology BRAF Caco-2 Cells Cancer EMBO24 EMBO37 Gene expression HCT116 Cells HT29 Cells Humans Indoles - pharmacology Kinases MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - physiology Molecular biology Mutation Niacinamide - analogs & derivatives Phenylurea Compounds PLX 4032/4720 Protein Kinase Inhibitors - pharmacology Protein Multimerization - drug effects Protein Multimerization - physiology Proto-Oncogene Proteins B-raf - metabolism Pyridines - pharmacology Signal transduction sorafenib Sulfonamides - pharmacology V600E-specific antibody |
title | Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T05%3A21%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinct%20requirement%20for%20an%20intact%20dimer%20interface%20in%20wild-type,%20V600E%20and%20kinase-dead%20B-Raf%20signalling&rft.jtitle=The%20EMBO%20journal&rft.au=R%C3%B6ring,%20Michael&rft.date=2012-05-30&rft.volume=31&rft.issue=11&rft.spage=2629&rft.epage=2647&rft.pages=2629-2647&rft.issn=0261-4189&rft.eissn=1460-2075&rft.coden=EMJODG&rft_id=info:doi/10.1038/emboj.2012.100&rft_dat=%3Cproquest_C6C%3E1018369830%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018695256&rft_id=info:pmid/22510884&rfr_iscdi=true |